The ADVANCE trial: Clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus

American Journal of Cardiovascular Drugs

Volumn 9, Issue 5, 2009, Pages 283-291

  Waeber, Bernard ^a   De La Sierra, Alejandro ^b   Ruilope, Luis M ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LOSARTAN; NISOLDIPINE; PERINDOPRIL; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; RAMIPRIL; URIC ACID;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM CELL; EVENING DOSAGE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DRUG COMBINATIONS; HUMANS; INDAPAMIDE; PERINDOPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70349755368     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/10061600-000000000-00000     Document Type: Review

References (54)

1. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360 (Pubitemid 35341298)
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
3. Murray CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996; 274: 740-743
4. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223 (Pubitemid 40138015)
5. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-317
6. Tarnow L, Rossing P, Gall MA, et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17: 1247-1251 (Pubitemid 24324966)
7. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130-1134 (Pubitemid 29230961)
8. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-325
9. Perneger TV, Brancati FL, Whelton PK, et al. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994; 121: 912-918 (Pubitemid 24370853)
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
11. Hansson L, Zanchetti A, Carruthers SG, et al., on behalf of the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762
12. Parving HH, Andersen AR, Smidt UM, et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1443-1447 (Pubitemid 17079619)
13. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869 (Pubitemid 34940825)
14. Lewis EJ, Hunsicker LG, Bain RP, et al., on behalf of the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
15. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860 (Pubitemid 34940824)
16. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878 (Pubitemid 34940826)
17. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
18. Pohl MA, Blumenthal S, Cordonnier DJ, et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037 (Pubitemid 44743500)
19. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419 (Pubitemid 40973424)
20. Ryden L, Standl E, Bartnik M, et al., on behalf of The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28: 88-136
21. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162-172 (Pubitemid 46052519)
22. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187 (Pubitemid 46924065)
23. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252 (Pubitemid 37553153)
24. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11-25 (Pubitemid 41818080)
25. Patel A, MacMahon S, Chalmers J, et al. Effects of fixed combination of perindopril and indapamide on microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controllled trial. Lancet 2007; 370: 829-840 (Pubitemid 47362321)
26. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572 (Pubitemid 351831357)
27. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure withmacrovascular andmicrovascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-419 (Pubitemid 30609443)
28. Stamler J. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444 (Pubitemid 23046633)
29. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913 (Pubitemid 35472129)
30. Zanchetti A, Hansson L, Clement D, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21: 797-804
31. Estacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 Suppl. 2: 54-64
32. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097 (Pubitemid 34175478)
33. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-1565 (Pubitemid 36835100)
34. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170-2179 (Pubitemid 41716450)
35. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259
36. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001; 38: E28-32
37. Laurent S. Evidence for benefits of perindopril in hypertension and its complications. Am J Hypertens 2005; 18: 155-62S (Pubitemid 41206572)
38. Ferrari R, Pasanisi G, Notarstefano P, et al. Specific properties and effect of perindopril in controlling the renin-angiotensin system. Am J Hypertens 2005; 18: 142-54S (Pubitemid 41206571)
39. Robinson DM, Wellington K. Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs 2006; 66: 257-271 (Pubitemid 43213906)
40. Campbell DB, Brackman F. Cardiovascular protective properties of indapamide. Am J Cardiol 1990; 65: 11-27H
41. Marre M, Puig JG, Kokot F, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613-1622 (Pubitemid 39037614)
42. Carey PA, Sheridan DJ, de Cordoue A, et al. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996; 77: 17-9b
43. Kuo SW, Pei D, Hung YJ, et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16: 623-628 (Pubitemid 36900583)
44. Kang S, Wu YF, An N, et al. A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clin Ther 2004; 26: 257-270
45. Gosse P. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection. Expert Rev Cardiovasc Ther 2006; 4: 319-333 (Pubitemid 43796990)
46. Mogensen CE, Viberti G, Halimi S, et al. Effect of low-dose perindopril/ indapamide on albuminuria in diabetes: Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063-1071 (Pubitemid 36548604)
47. Giugliano D, Marfella R, Acampora R, et al. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998; 21: 631-636 (Pubitemid 28172947)
48. Fogari R, Mugellini A, Zoppi A, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 316-320 (Pubitemid 34408970)
49. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006; 48: 80-86 (Pubitemid 44313590)
50. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041 (Pubitemid 32925123)
51. Berthet K, Neal BC, Chalmers JP, et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004; 13: 7-13 (Pubitemid 38455840)
52. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapywith the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23: 1999-2010 (Pubitemid 34073191)
53. Staessen JA, Wang JG, Thijs L. What can be expected from optimal blood pressure control? J Hypertens 2003; 21 Suppl.: 3-9
54. de Galan BE, Perkovic V, Ninomiya T, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892